Imperial College released a press release on the 26th saying that a vaccine candidate aimed at preventing rhinovirus infections has achieved encouraging initial results in phase 1 clinical trials. The vaccine was well tolerated by healthy volunteers and developed an immune response against 3 major rhinoviruses after a single dose. The vaccine candidate, called APL-10456, was developed by Imperial College in collaboration with a biopharmaceutical company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.